| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/05/2004 | WO2003055911A8 Cystine-knot fold protein |
| 02/05/2004 | WO2003048390A8 A process for the preparation of a non-toxic anthrax vaccine |
| 02/05/2004 | WO2003046137A3 Hiv envelope v3-ccr5 binding site immunogen |
| 02/05/2004 | WO2003024354A3 Interleukin-12 as a veterinary vaccine adjuvant |
| 02/05/2004 | WO2003016915A8 Tumor specific oligosaccharide sequences and use thereof |
| 02/05/2004 | WO2003004525A3 Isolation and purification of plasmodium falciparum merozoite protein-142 |
| 02/05/2004 | US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders |
| 02/05/2004 | US20040025196 Comprises nucleotide sequences coding proteins with plenty of SH3 domains (POSH) for preventing viral and bacterial infection and replication; rational drug design; viricides; antiapoptosis agents; bactericides |
| 02/05/2004 | US20040024181 Comprises polypeptide for treatment, diagnosis, and prevention of cancer, inflammation, nervous system disorders, learning and memory defects and sexual disorders |
| 02/05/2004 | US20040024058 Vaccine preparation containing fatty acid as component |
| 02/05/2004 | US20040023909 Process for preventing or reducing undesirable immunological effects to infectious agents in subjects |
| 02/05/2004 | US20040023885 Islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided |
| 02/05/2004 | US20040023881 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023872 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/05/2004 | US20040023865 Polypeptides that contain at least one antigenic portion of a B. microti antigen and DNA sequences encoding such polypeptides. Antigenic epitopes of such antigens are also provided, together with pharmaceutical compositions and |
| 02/05/2004 | US20040023358 Avian embryo particulate biomass for the production of virus antigens |
| 02/05/2004 | US20040023340 Method for producing human anti-thymocyte immunoglobulins |
| 02/05/2004 | US20040023339 Transgenic cell culture for preparing monoclonal antibodies for treatment and prevention of cancer |
| 02/05/2004 | US20040023337 IL-13 mutein proteins, antibodies, compositions, methods and uses |
| 02/05/2004 | US20040023334 Comprises lactoferrin fusion protein for diagnosis, prevention treatment and prognosis of nervous system, respiratory, cardiovascular and/or reproductive system disorders |
| 02/05/2004 | US20040023332 Genes of il-12p40 subunit mutated for improving the activity of il-12 and thereof for dna vaccine adjuvant |
| 02/05/2004 | US20040023327 Using site directed mutagenesis to cause nucleotide sequences alterations in target protein; polypeptide engineering |
| 02/05/2004 | US20040023325 Comprises genetically engineered outer surface protein for use in treatment and prevention of lyme disease; genetic vaccines |
| 02/05/2004 | US20040023314 Identifying cells that will differentiate into metastatic cancer via presence of increased concentration of aberrant cell adhesion molecule and decrease in cellular matrix formation |
| 02/05/2004 | US20040023313 Comprises monoclonal antibody which specifically binds osteoprotegerin ligand (OPGL) for diagnosis, prevention and treatment of bone disorders |
| 02/05/2004 | US20040023307 DNA encoding a novel RG1 polypeptide |
| 02/05/2004 | US20040023291 Comprises insect polypeptide for use in hemolysis and immunosuppression; immunotherapy |
| 02/05/2004 | US20040023290 Novel therapeutic agents that modulate enzymatic processes |
| 02/05/2004 | US20040023278 Sialoadhesin family member-2 (SAF-2) |
| 02/05/2004 | US20040023215 Methods and compositions employing the nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases |
| 02/05/2004 | US20040022870 Immunogenic TLP composition |
| 02/05/2004 | US20040022840 Nanoparticle vaccines |
| 02/05/2004 | US20040022814 For use in vaccine |
| 02/05/2004 | US20040022813 Shed antigen vaccine with dendritic cells adjuvant |
| 02/05/2004 | US20040022811 For use in diagnosis, prophylaxis |
| 02/05/2004 | US20040022810 Immunomodulatory preparation |
| 02/05/2004 | US20040022809 Cold-adapted equine influenza viruses |
| 02/05/2004 | US20040022808 Use of a split enveloped virus preparation which is not a split influenza virus preparation in the manufacture of vaccine formulation for itranasal delivery |
| 02/05/2004 | US20040022805 Useful for incorporation into the DNA vaccine vectors; for prophylaxis and therapy of malaria |
| 02/05/2004 | US20040022804 Administering protein Q or a variant thereof containing modifications or substitutions of preserved amino acid residues, protein Q or variant thereof being optionally combined with complete or fragmented protein LiHsp70 and |
| 02/05/2004 | US20040022802 Surface proteins of Leptospira |
| 02/05/2004 | US20040022801 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/05/2004 | US20040022800 Respiratory syncytial virus vaccine |
| 02/05/2004 | US20040022798 Can stored for several years, and which are ready to use after thawing |
| 02/05/2004 | US20040022796 Administering an HSP/ alpha 2M vaccine composition comprising an HSP or alpha 2M complexed to a component against which an immune response is desired to be induced; administering heat shock protein preparation |
| 02/05/2004 | US20040022795 Protective antigens for the control of Ixodes species infestations |
| 02/05/2004 | US20040022793 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 02/05/2004 | US20040022792 Adding a quantity of one or more amino acids to the preparation sufficient to reduce the degree of aggregation of the protein to less than that of the protein without the amino acid, and reducing the pH of the preparation |
| 02/05/2004 | US20040022791 Use of the heavy chain of an antibody, of a functional derivative, or of a fragment thereof, comprising a CDR3 region for jointly inhibiting fibrinogen binding to platelets and vitronectin binding to endothelial cells |
| 02/05/2004 | US20040022785 Expression of herstatin, an alternative HER-2/neu product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth |
| 02/05/2004 | US20040022783 Binding agents to CD23 |
| 02/05/2004 | US20040022782 Cyclitol containing carbohydrates from human tissue which regulate glycogen metabolism |
| 02/05/2004 | US20040022781 Proteins and nucleic acids encoding same |
| 02/05/2004 | US20040022774 Fibrocyte-based vaccine formulations |
| 02/05/2004 | US20040022770 Eliciting an immune response against prostate specific antigen (PSA) in a mammal by administering an effective amount of a recombinant bacille Calmette-Guerin (rBCG) strain expressing PSA |
| 02/05/2004 | US20040022768 Process useful for producing selective immune down regulation (SIDR) in subjects, including adult subjects to artificially expressed gene, gene delivery systems, infectious agents, and non-cellular immunogenic components, and processes for producing immunological tolerance in subjets using SIDR |
| 02/05/2004 | US20040022762 Use of il-8 protein modulators in the treatment of viral infections |
| 02/05/2004 | US20040022760 Administering Flt3-ligand to a subject; optionally administering an auxiliary molecule; administering a vaccine to the subject, wherein the vaccine comprises an antigen and an adjuvant |
| 02/05/2004 | DE10233064A1 gM-negative EHV-Mutanten ohne heterologe Elemente gM-negative EHV mutants without heterologous elements |
| 02/05/2004 | CA2727782A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2494485A1 Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| 02/05/2004 | CA2493782A1 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 02/05/2004 | CA2493590A1 Auto-stimulating cells and method for making and using the same |
| 02/05/2004 | CA2492858A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | CA2492447A1 Taci antibodies and uses thereof |
| 02/05/2004 | CA2492444A1 Modified adamts4 molecules and method of use thereof |
| 02/05/2004 | CA2492333A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2492295A1 Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion |
| 02/05/2004 | CA2484941A1 Antigens encoded by alternative reading frame from pathogenic viruses |
| 02/04/2004 | EP1386933A1 Cytokine antagonists and agonists |
| 02/04/2004 | EP1386932A1 Improved humanized immunoglobulins |
| 02/04/2004 | EP1386931A1 Human neurotrimin homologue |
| 02/04/2004 | EP1386929A1 Peptides associated with tumors and uses related thereto |
| 02/04/2004 | EP1386660A1 Isolation of proteins |
| 02/04/2004 | EP1386617A1 Method for the in vitro diagnosis of type II porcine circovirus infection and diagnostic reagents |
| 02/04/2004 | EP1386616A1 Antibordetella vaccine |
| 02/04/2004 | EP1386615A1 EG-VEGF/Prokineticin 2 receptor antagonists |
| 02/04/2004 | EP1386165A2 Inflammatory markers for detection and prevention of diabetes mellitus |
| 02/04/2004 | EP1386162A2 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 02/04/2004 | EP1386155A2 Therapeutic and diagnostic uses of antibody specificity profiles |
| 02/04/2004 | EP1386152A2 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes |
| 02/04/2004 | EP1385993A2 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 02/04/2004 | EP1385988A2 Selective covalent-binding compounds having therapeutic diagnostic and analytical applications |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385959A2 Method of producing recombinant antibodies against tumours |
| 02/04/2004 | EP1385955A2 Cell adhesion proteins |
| 02/04/2004 | EP1385954A2 Proteins associated with cell growth, differentiation, and death |
| 02/04/2004 | EP1385953A2 Proteins and nucleic acids encoding same |
| 02/04/2004 | EP1385886A1 Method for preparing human immunoglobulin concentrates for therapeutic use |
| 02/04/2004 | EP1385876A2 Gonococcal proteins and nucleic acids |
| 02/04/2004 | EP1385875A2 Epitopes of virus hepatitis c specifically cd4+ t-lymphocytes |
| 02/04/2004 | EP1385864A1 Vascular endothelial growth factor 2 |
| 02/04/2004 | EP1385861A2 Compositions and methods relating to lung specific genes and proteins |
| 02/04/2004 | EP1385554A2 Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins |
| 02/04/2004 | EP1385547A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 02/04/2004 | EP1385546A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents |
| 02/04/2004 | EP1385545A2 Humanized antibodies |
| 02/04/2004 | EP1385544A2 Humanized antibodies |
| 02/04/2004 | EP1385543A1 Human medical treatment by application of immunoglobulin a |